Nausea is a discomforting feeling that is typically associated with vomiting. Nausea can occur as a result of motion sickness during a long turbulent plane or car ride, or it can be the result of an inner ear problem that results in excessive...
Nausea, which is the sensation of the need to vomit, is a common side effect of chemotherapy treatment for cancer. The probability of experiencing nausea is dependent upon the specific drug used, the dosage of the drug administered, and whether...
Comprehensive and accurate Emend side effects information for consumers and healthcare professionals.
Consumer information about the medication APREPITANT - ORAL (Emend), includes side effects, drug interactions, recommended dosages, and storage information. Read more ...
Comprehensive and accurate Aprepitant side effects information for consumers and healthcare professionals.
Common Emend side effects may include diarrhea, hair loss, and loss of appetite. This page from the eMedTV site lists other potential side effects of Emend, including ...
Aprepitant Side Effects. The drug generically named aprepitant is used as a secondary treatment to chemotherapy for cancer patients. Aprepitant, alongside other drugs ...
EMEND may cause serious side effects, including allergic reactions such as hives, rash, itching, and trouble breathing or swallowing. Stop taking EMEND and call your ...
Weakness, fatigue, hiccups, and hair loss are the most common side effects of aprepitant. This eMedTV page describes other common aprepitant side effects, lists rare ...
Emend is used to help prevent or reduce nausea and/or vomiting that can occur during chemotherapy treatment or following surgery. Learn more about Emend at ...
EMEND for Injection may cause serious side effects, including sudden allergic reactions. Tell your doctor or nurse right away if you have flushing or redness of your ...
Emend side effects may include feeling like you might pass out, feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin; or, fever ...
